News | October 01, 2007

TherOx to Unveil SuperOxygenation Study Results at TCT

October 2, 2007 - TherOx Inc., a privately held medical device company, will announce at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C. on October 23, the results from its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), designed to introduce a new therapy developed by THEROX called SuperOxygenation Therapy.

The multi-center, randomized trial included more than 300 STEMI (ST-segment Elevation Myocardial Infarction) patients and introduced a new treatment category called Myocardial Salvage Intervention (MSI). SuperOxygenation Therapy is an adjunctive therapy performed immediately after Percutaneous Coronary Intervention (PCI) in Acute Myocardial Infarction (AMI) patients. Myocardial Salvage Intervention is a new treatment category for AMI patients designed to salvage the jeopardized myocardium and reduces infarct size.

AMIHOT II was derived from a subset of the original AMIHOT study population consisting of anterior AMI patients treated within 6 hours from symptom onset. Effectiveness was assessed by infarct size reduction measured by SPECT at 14 days post event, and safety was determined by the 30-day MACE (Major Adverse Cardiac Events) rate. MACE comprised combined incidence of death, reinfarction, target vessel revascularization and stroke.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init